Stocks and Investing
Stocks and Investing
Fri, June 16, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Eddie Hickman Maintained (TARS) at Strong Buy with Increased Target to $42 on, Jun 16th, 2023
Eddie Hickman of Guggenheim, Maintained "Tarsus Pharmaceuticals, Inc." (TARS) at Strong Buy with Increased Target from $40 to $42 on, Jun 16th, 2023.
Eddie has made no other calls on TARS in the last 4 months.
There are 2 other peers that have a rating on TARS. Out of the 2 peers that are also analyzing TARS, 0 agree with Eddie's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Eddie
- Francois Brisebois of "Oppenheimer" Reiterated at Buy and Held Target at $43 on, Monday, May 8th, 2023
- Oren Livnat of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $40 on, Wednesday, March 15th, 2023
Contributing Sources